Predictive biomarkers of colon cancer immunotherapy: Present and future
W Hou, C Yi, H Zhu - Frontiers in immunology, 2022 - frontiersin.org
Immunotherapy has revolutionized colon cancer treatment. Immune checkpoint inhibitors
(ICIs) have shown clinical benefits for colon cancer patients, especially those with high …
(ICIs) have shown clinical benefits for colon cancer patients, especially those with high …
Liquid biopsies to monitor and direct cancer treatment in colorectal cancer
Colorectal cancer (CRC) is one of the most prevalent and deadly cancers worldwide.
Despite recent improvements in treatment and prevention, most of the current therapeutic …
Despite recent improvements in treatment and prevention, most of the current therapeutic …
The status of tumor mutational burden and immunotherapy
Tumor mutational burden (TMB) has received significant attention within ongoing pursuits of
biomarkers of response to immune checkpoint inhibitors, and notably received FDA …
biomarkers of response to immune checkpoint inhibitors, and notably received FDA …
Lynch syndrome and MSI-H cancers: from mechanisms to “off-the-shelf” cancer vaccines
V Roudko, C Cimen Bozkus, B Greenbaum… - Frontiers in …, 2021 - frontiersin.org
Defective DNA mismatch repair (dMMR) is associated with many cancer types including
colon, gastric, endometrial, ovarian, hepatobiliary tract, urinary tract, brain and skin cancers …
colon, gastric, endometrial, ovarian, hepatobiliary tract, urinary tract, brain and skin cancers …
Immune escape and resistance to immunotherapy in mismatch repair deficient tumors
G Mestrallet, M Brown, CC Bozkus… - Frontiers in …, 2023 - frontiersin.org
Up to 30% of colorectal, endometrial and gastric cancers have a deficiency in mismatch
repair (MMR) protein expression due to either germline or epigenetic inactivation. Patients …
repair (MMR) protein expression due to either germline or epigenetic inactivation. Patients …
Avelumab vs standard second-line chemotherapy in patients with metastatic colorectal cancer and microsatellite instability: a randomized clinical trial
Importance Only 1 randomized clinical trial has shown the superiority of immune checkpoint
inhibitors in patients with deficient mismatch repair and/or microsatellite instability …
inhibitors in patients with deficient mismatch repair and/or microsatellite instability …
Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update
AE Boukouris, M Theochari, D Stefanou… - Critical reviews in …, 2022 - Elsevier
The long-term remissions induced by immune-checkpoint inhibitors (ICIs) in many types of
cancers have opened up the possibility of a broader use of immunotherapy in less …
cancers have opened up the possibility of a broader use of immunotherapy in less …
The hippo pathway effectors YAP/TAZ-TEAD oncoproteins as emerging therapeutic targets in the tumor microenvironment
Simple Summary YAP/TAZ are the central effectors of the Hippo pathway and orchestrate
their oncogenic program by binding to TEAD transcriptional factors. Here, we document a …
their oncogenic program by binding to TEAD transcriptional factors. Here, we document a …
[HTML][HTML] Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance
V Amodio, S Lamba, R Chilà, CM Cattaneo, B Mussolin… - Cancer Cell, 2023 - cell.com
Patients affected by colorectal cancer (CRC) with DNA mismatch repair deficiency (MMRd),
often respond to immune checkpoint blockade therapies, while those with mismatch repair …
often respond to immune checkpoint blockade therapies, while those with mismatch repair …
[HTML][HTML] Engineering neoantigen vaccines to improve cancer personalized immunotherapy
Z Liu, J Lv, Q Dang, L Liu, S Weng, L Wang… - … journal of biological …, 2022 - ncbi.nlm.nih.gov
Immunotherapy treatments harnessing the immune system herald a new era of personalized
medicine, offering considerable benefits for cancer patients. Over the past years, tumor …
medicine, offering considerable benefits for cancer patients. Over the past years, tumor …